IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril) -Induced Cough: a Pharmacogenetic Study
Luo, Jian-Quan1,2,3; He, Fa-Zhong1,2,3; Wang, Zhen-Min1,2,3; Sun, Ning-Ling4; Wang, Lu-Yan4; Tang, Gen-Fu5; Liu, Mou-Ze1,2,3; Li, Qing1,2,3; Chen, Xiao-Ping1,2,3; Liu, Zhao-Qian1,2,3; Zhou, Hong-Hao1,2,3; Zhang, Wei1,2,3
刊名SCIENTIFIC REPORTS
2015-11-26
DOI10.1038/srep17253
5
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]TRANSPORTING POLYPEPTIDE 1B1 ; SIMVASTATIN-INDUCED MYOPATHY ; STATIN-INDUCED MYOPATHY ; REFLEX SENSITIVITY ; GENETIC-POLYMORPHISM ; INDUCED ANGIOEDEMA ; PHARMACOKINETICS ; ACE ; PRAVASTATIN ; HAPLOTYPES
英文摘要

Clinical observations suggest that incidence of cough in Chinese taking angiotensin converting enzyme inhibitors is much higher than other racial groups. Cough is the most common adverse reaction of enalapril. We investigate whether SLCO1B1 genetic polymorphisms, previously reported to be important determinants of inter-individual variability in enalapril pharmacokinetics, are associated with the enalapril-induced cough. A cohort of 450 patients with essential hypertension taking 10 mg enalapril maleate were genotyped for the functional SLCO1B1 variants, 388A > G (Asn130Asp, rs2306283) and 521T > C (Val174Ala, rs4149056). The primary endpoint was cough, which was recorded when participants were bothered by cough and respiratory symptoms during enalapril treatment without an identifiable cause. SLCO1B1 521C allele conferred a 2-fold relative risk of enalapril-induced cough (95% confidence interval [CI] = 1.34-3.04, P = 6.2 x 10(-4)), and haplotype analysis suggested the relative risk of cough was 6.94-fold (95% CI = 1.30-37.07, P = 0.020) in SLCO1B1*15/*15 carriers. Furthermore, there was strong evidence for a gene-dose effect (percent with cough in those with 0, 1, or 2 copy of the 521C allele: 28.2%, 42.5%, and 71.4%, trend P = 6.6 x 10(-4)). Our study highlights, for the first time, SLCO1B1 variants are strongly associated with an increased risk of enalapril-induced cough. The findings will be useful to provide pharmacogenetic markers for enalapril treatment.

语种英语
WOS记录号WOS:000365383600001
项目编号2012AA02A517 ; 2012AA02A518 ; 81522048 ; 81573511 ; 81273595 ; 81302850 ; CX2014B100
资助机构National High Technology Research and Development Program of China, "863" Project ; National Scientific Foundation of China ; Hunan Provincial Innovation Foundation for Postgraduate
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66097
专题北京大学第二临床医学院_心血管内科
作者单位1.Anhui Med Univ, Sch Hlth Adm, Hefei 230032, Peoples R China
2.Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
3.Cent S Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
4.Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang 421001, Peoples R China
5.Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Luo, Jian-Quan,He, Fa-Zhong,Wang, Zhen-Min,et al. SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril) -Induced Cough: a Pharmacogenetic Study[J]. SCIENTIFIC REPORTS,2015,5.
APA Luo, Jian-Quan.,He, Fa-Zhong.,Wang, Zhen-Min.,Sun, Ning-Ling.,Wang, Lu-Yan.,...&Zhang, Wei.(2015).SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril) -Induced Cough: a Pharmacogenetic Study.SCIENTIFIC REPORTS,5.
MLA Luo, Jian-Quan,et al."SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril) -Induced Cough: a Pharmacogenetic Study".SCIENTIFIC REPORTS 5(2015).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Luo, Jian-Quan]的文章
[He, Fa-Zhong]的文章
[Wang, Zhen-Min]的文章
百度学术
百度学术中相似的文章
[Luo, Jian-Quan]的文章
[He, Fa-Zhong]的文章
[Wang, Zhen-Min]的文章
必应学术
必应学术中相似的文章
[Luo, Jian-Quan]的文章
[He, Fa-Zhong]的文章
[Wang, Zhen-Min]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。